ASRT: Assertio Holdings, Inc. Stock

by

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 59.37
Enterprise Value ($M) 63.29
Book Value ($M) 108.53
Book Value / Share 1.13
Price / Book 0.55
NCAV ($M) 35.65
NCAV / Share 0.37
Price / NCAV 1.67

Profitability (mra)
Return on Invested Capital (ROIC) -0.20
Return on Assets (ROA) -0.11
Return on Equity (ROE) -0.23

Liquidity (mrq)
Quick Ratio 1.35
Current Ratio 1.66

Balance Sheet (mrq) ($M)
Current Assets 213.55
Assets 286.43
Liabilities 177.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 124.96
Operating Income -14.22
Net Income -21.58
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 26.41
Cash from Investing -48.91
Cash from Financing -0.35

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 0.00 -100.00
11-14 13G/A Nantahala Capital Management, LLC 9.39 17.44
11-12 13G/A Vanguard Group Inc 4.68 0.00
07-08 13G/A BlackRock, Inc. 1.50 -78.92

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-14 73,569 319,655 23.02
2025-05-13 175,418 597,910 29.34
2025-05-12 121,177 286,164 42.35
2025-05-09 98,474 250,556 39.30

(click for more detail)

Similar Companies
APVO – Aptevo Therapeutics Inc. ARTL – Artelo Biosciences, Inc.
ASNS – Actelis Networks, Inc. ATHA – Athira Pharma, Inc.
ATNF – 180 Life Sciences Corp.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.